| __timestamp | Bausch Health Companies Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 14400000 |
| Thursday, January 1, 2015 | 2645000000 | 33800000 |
| Friday, January 1, 2016 | 2611000000 | 35900000 |
| Sunday, January 1, 2017 | 2548000000 | 1254000 |
| Monday, January 1, 2018 | 2351000000 | 4889000 |
| Tuesday, January 1, 2019 | 2350000000 | 7400000 |
| Wednesday, January 1, 2020 | 2249000000 | 10100000 |
| Friday, January 1, 2021 | 2394000000 | 14300000 |
| Saturday, January 1, 2022 | 2364000000 | 23200000 |
| Sunday, January 1, 2023 | 2559000000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Unlocking the unknown
In the ever-evolving landscape of the pharmaceutical industry, understanding the cost dynamics is crucial. This analysis delves into the cost of revenue for two prominent players: Bausch Health Companies Inc. and Neurocrine Biosciences, Inc. Over the past decade, Bausch Health has consistently maintained a high cost of revenue, averaging around $2.4 billion annually. In contrast, Neurocrine Biosciences has shown a more modest average of approximately $18 million, reflecting its different business model and scale.
From 2014 to 2023, Bausch Health's cost of revenue fluctuated slightly, peaking in 2015 and 2023. Meanwhile, Neurocrine Biosciences experienced a significant increase, with a 175% rise from 2014 to 2023. This stark contrast highlights the diverse strategies and market positions of these companies. As the industry continues to grow, monitoring these trends offers valuable insights into their financial health and strategic direction.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Cost Insights: Breaking Down Bausch Health Companies Inc. and Vericel Corporation's Expenses
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited